What Happened?
Watertown, MA-based Werner Cautreels Appointed as Chief Executive Officer
About the Company
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.
About the Person
Werner Cautreels is the Chief Executive Officer of Selecta Biosciences. Prior to joining Selecta Biosciences, Dr. Cautreels was CEO of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group (Brussels, Belgium) until Solvay Pharmaceuticals was acquired by Abbott Laboratories in February 2010. Before becoming the CEO of Solvay Pharmaceuticals, Dr. Cautreels was their Global Head of R&D. Prior to joining Solvay, he was employed by Sanofi, Sterling-Winthrop, and Nycomed-Amersham in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels was a director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, MA, USA) from 1999-2006. He is currently a director of Selecta and Galapagos NV (Mechelen, Belgium). He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He was born in Antwerp, Belgium, and graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He received his management education from the Harvard Business School.
Info Source
Press Release
Short Profile